 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
10 News |  |
- AB-836 / Arbutus
Hepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836 (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_2079;
No viral breakthrough or enrichment of HBV core protein resistant variants was observed in subjects receiving AB-836 for 28 days. Multiple core protein variants at amino acid positions Y38, I105, T109, T114, and I116 were observed to occur at higher frequencies, suggesting viral plasticity at these sites.
- |||| AB-836 / Arbutus
Trial termination: Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection (clinicaltrials.gov) - Nov 21, 2022
P1, N=110, Terminated, Sponsor: Arbutus Biopharma Corporation
Multiple core protein variants at amino acid positions Y38, I105, T109, T114, and I116 were observed to occur at higher frequencies, suggesting viral plasticity at these sites. Recruiting --> Terminated; Safety
- || AB-836 / Arbutus
Enrollment change, Trial completion date, Trial primary completion date: Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection (clinicaltrials.gov) - Oct 28, 2022
P1, N=110, Recruiting, Sponsor: Arbutus Biopharma Corporation
Recruiting --> Terminated; Safety N=60 --> 110 | Trial completion date: Aug 2022 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Jan 2023
- AB-836 / Arbutus
Rational design of a novel series of HBV capsid inhibitors leading to the identification of clinical candidate AB-836 (W183a (McCormick Place Convention Center)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_11435;
Initial data from a phase 1b proof of concept study in chronic hepatitis B patients receiving a once daily 100 mg dose of AB-836 for 28 days (N=4) showed robust antiviral activity with a mean reduction of 3.1 log10 in HBV DNA from baseline. The excellent preclinical profile and emerging clinical data support further development of AB-836.
- AB-836 / Arbutus, AB-729 / Arbutus
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1751;
Robust antiviral activity was observed at Day 28 of treatment. These results support further evaluation of AB-836 alone and in combination with other agents, including the GalNAc siRNA AB-729, in CHB subjects.
- ||| AB-836 / Arbutus
Enrollment open: Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection (clinicaltrials.gov) - Jun 21, 2021
P1, N=60, Recruiting, Sponsor: Arbutus Biopharma Corporation
These results support further evaluation of AB-836 alone and in combination with other agents, including the GalNAc siRNA AB-729, in CHB subjects. Not yet recruiting --> Recruiting
- AB-836 / Arbutus
[VIRTUAL] Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor () - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1052;
Not yet recruiting --> Recruiting AB-836 is a novel class II capsid inhibitor that showed potent, selective inhibition of HBV in vitro and in vivo, with a unique binding mode to core protein, and a favorable preclinical profile for clinical advancement.
- ||| AB-836 / Arbutus
New P1 trial: Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection (clinicaltrials.gov) - Feb 28, 2021
P1, N=60, Not yet recruiting, Sponsor: Arbutus Biopharma Corporation
- core protein/capsid assembly inhibitors / Arbutus
A NOVEL HBV CAPSID INHIBITOR COMPOUND SERIES DEMONSTRATES IMPROVED INHIBITION OF HBV WT AND T33N CORE PROTEIN VARIANT AND SHOWS A UNIQUE BINDING MODE TO CORE PROTEIN (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_3061;
AB-836 is a novel class II capsid inhibitor that showed potent, selective inhibition of HBV in vitro and in vivo, with a unique binding mode to core protein, and a favorable preclinical profile for clinical advancement. HBV capsid inhibitors from a novel chemotype showed a unique binding mode to HBV core protein when compared to previously reported X-ray structures and demonstrated improved antiviral properties in vitro in comparison to previous generation of capsid inhibitors.